Effect of Intravenous IgM-Enriched Immunoglobulins on Presepsin and Other Sepsis Biomarkers.
elderly
immunoglobulin M
presepsin (soluble CD14-subtype)
sepsis - diagnostics
septic shock (MeSH)
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
05
2021
accepted:
25
08
2021
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
Patients in septic shock with low IgG and IgM serum concentrations have higher mortality rates compared to those with normal immunoglobulin levels and, therefore, there is a rational explanation to administer intravenous IgM-enriched immunoglobulins to septic patients in ICU. Aim of this study is to evaluate the effectiveness of intravenous IgM-enriched immunoglobulins in decreasing several sepsis biomarker concentrations. 26 sepsis patients were enrolled in this observational cohort study and Nitric Oxide, Endocan, Pentraxin and presepsin serum levels were measured during their first 3 days of ICU stay. The use of intravenous IgM-enriched immunoglobulins did not influence the temporal evolution of SOFA, Nitric Oxide, Endocan, Pentraxin and Presepsin in the first 3 days of ICU stay in a statistically significant manner, even if Presepsin decreased of 25% from day 1 to day 2 in the Pentaglobin group. It seems possible that Pentaglobin infusion reduces the Presepsin level in a more effective way if it were administered to a younger population (
Identifiants
pubmed: 34566642
doi: 10.3389/fphar.2021.717349
pii: 717349
pmc: PMC8455986
doi:
Types de publication
Journal Article
Langues
eng
Pagination
717349Informations de copyright
Copyright © 2021 Scarpati, Baldassarre, Tripepi, Boffardi and Piazza.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immunobiology. 2017 Dec;222(12):1074-1080
pubmed: 28911957
Am J Epidemiol. 2007 Mar 15;165(6):710-8
pubmed: 17182981
Ann Intensive Care. 2019 Feb 6;9(1):27
pubmed: 30725235
Ann Intensive Care. 2020 Oct 7;10(1):132
pubmed: 33026597
Shock. 2010 May;33(5):556-7; author reply 557
pubmed: 20395773
Drug Saf. 1999 Sep;21(3):171-85
pubmed: 10487396
Int J Tuberc Lung Dis. 2004 Oct;8(10):1173-9
pubmed: 15527148
Ann Clin Biochem. 2003 Mar;40(Pt 2):143-8
pubmed: 12662402
Front Med (Lausanne). 2020 Jul 16;7:388
pubmed: 32766266
Intensive Care Med. 2014 Dec;40(12):1888-96
pubmed: 25217146
Clin Microbiol Infect. 2016 Jun;22(6):499-506
pubmed: 26850828
Emerg Infect Dis. 2003 Sep;9(9):1064-9
pubmed: 14519241
BMJ Open. 2021 Feb 11;11(2):e036616
pubmed: 33574139
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
World J Crit Care Med. 2012 Feb 04;1(1):23-30
pubmed: 24701398